Wellington Management Group’s Freeline Therapeutics Holdings FRLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-29,320
Closed -$866K – 2267
2021
Q4
$866K Sell
29,320
-15,002
-34% -$613K ﹤0.01% 1827
2021
Q3
$2.29M Sell
44,322
-89,141
-67% -$6.34M ﹤0.01% 1662
2021
Q2
$16.3M Sell
133,463
-14,343
-10% -$2.23M ﹤0.01% 1139
2021
Q1
$27.3M Sell
147,806
-8,979
-6% -$2.13M ﹤0.01% 993
2020
Q4
$42.9M Buy
156,785
+23,250
+17% +$5.84M 0.01% 810
2020
Q3
$31.3M Buy
+133,535
New +$33.5M 0.01% 833

Other funds holding FRLN

Wellington Management Group's FRLN Position: Q1 2022 in Review

Wellington Management Group sold out of Freeline Therapeutics Holdings (FRLN) in Q1 2022, closing a stake of 29,320 shares — an estimated $866K sold.

Wellington Management Group first reported a position in FRLN in Q3 2020 and held it in 6 quarters. The position peaked at $42.9M in Q4 2020. 19 funds tracked by Wall St. Rank hold FRLN as of Q1 2022.

  • Wellington Management Group reported no remaining Freeline Therapeutics Holdings position as of Q1 2022 after selling out during the quarter.
  • Wellington Management Group sold 29,320 Freeline Therapeutics Holdings shares in Q1 2022, an estimated $866K.
  • Wellington Management Group first reported a position in Freeline Therapeutics Holdings in Q3 2020 and held it in 6 quarters.
  • Wellington Management Group's Freeline Therapeutics Holdings position peaked at $42.9M in Q4 2020.
  • 19 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q1 2022.

Based on Wellington Management Group's 13F filing for Q1 2022, filed 16 May 2022.